Multi–panel immunofluorescence evaluation of tumor infiltrating lymphocytes in triple adverse breast most cancers: Evolution of tumor immune profiles and affected person prognosis.
- The evolutionary adjustments in immune profiles of triple adverse breast most cancers (TNBC) aren’t properly understood, though it’s identified that immune checkpoint inhibitors have diminished exercise in closely pre-treated TNBC sufferers. This examine was designed to characterize immune profile adjustments of longitudinal tumor specimens by learning immune subsets of tumor infiltrating lymphocytes (TILs) in paired main and metastatic TNBC in a cohort of “poor end result” (relapsed inside 5 years) sufferers.
- Immune profiles of TNBCs in a cohort of “good end result” (no relapse inside 5 years) sufferers have been additionally analyzed. Immune subsets have been characterised for CD4, CD8, FOXP3, CD20, CD33, and PD1 utilizing immuno-fluorescence staining in stroma, tumor, and mixed stroma and tumor tissue. TIL subsets in “good end result” versus “poor end result” sufferers have been additionally analyzed. In contrast with main, metastatic TNBCs had considerably decrease TILs by hematoxylin and eosin (H&E) staining.
HAV HAV P2C recombinant antigen
- Stromal TILs (sTILs), however not tumoral TILs (tTILs) had considerably lowered cytotoxic CD8+ T cells (CTLs), PD1+ CTLs, and whole PD1+ TILs in metastatic in contrast with matched main TNBCs. Greater PD1+ CTLs, PD1+CD4+ helper T cells (PD1+TCONV) and all PD1+ T cells in sTILs, tTILs and whole stromal and tumor TILS (s+tTIL) have been all related to higher prognosis.
- In abstract, TIL subsets lower considerably in metastatic TNBCs in contrast with matched main. Hellogher PD1+ TILs are related to higher prognosis in early stage TNBCs. This discovering helps the appliance of immune checkpoint inhibitors early within the remedy of TNBCs
Tetranectin (CLEC3B) Antibody
Human Anti-Merozoite surface protein-1 (MSP-1; P. falciparum/malaria vaccine) IgG antiserum negative control |
970-360-01N |
Alpha Diagnostics |
1 ml |
EUR 196.8 |
Human Anti-Merozoite surface protein-1 (MSP-1; P. falciparum/malaria vaccine) IgG antiserum positive control |
970-360-02P |
Alpha Diagnostics |
1 ml |
EUR 270 |
Human Anti-Merozoite surface protein-1 (MSP-1; P. falciparum/malaria vaccine) IgM antiserum negative control |
970-370-01N |
Alpha Diagnostics |
1 ml |
EUR 196.8 |
Human Anti-Merozoite surface protein-1 (MSP-1; P. falciparum/malaria vaccine) IgM antiserum positive control |
970-370-02P |
Alpha Diagnostics |
1 ml |
EUR 270 |
Recombinant flagellin FlicC vaccine adjuvant (TLR5 agonist); vaccine adjuvant |
AV-7010-50 |
Alpha Diagnostics |
50 ug |
EUR 1074 |
Saponin Vaccine Adjuvant |
VAdv-Ly0009 |
Creative Biolabs |
1 g |
EUR 1314 |
Description: Saponin Vaccine Adjuvant, plant-based vaccine adjuvant. |
Bordetella bronchiseptica proteins (inactivated vaccine for dog) for ELISA |
BBV15-N-100 |
Alpha Diagnostics |
100 ug |
EUR 343.2 |
Rabbit Anti-West Nile Virus vaccine (WNV, Recombitek/DNA vaccine) antiserum |
WNV13-S |
Alpha Diagnostics |
100 ul |
EUR 548.4 |
SARS-CoV-2 Spike RBD ELISA Kit (For Vaccine Development) |
RAS-A050 |
ACROBIOSYSTEMS |
96tests |
EUR 631.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike Protein RBD is urgently needed to accelerate the development of COVID-19 vaccines. |
Rabies virus Glycoprotein G ELISA Kit (For Vaccine Development) |
RAS-A167 |
ACROBIOSYSTEMS |
96tests |
EUR 631.3 |
|
Description: Rabies virus (RABV), scientific name Rabies lyssavirus, is a deadly neurotropic virus that causes rabies in humans and animals. Rabies virus has an extremely wide host range and its transmission most often occur through the saliva of animals. Without intervention prior to disease progression, rabies has the highest case fatality of any infectious disease. RABV contains a single-stranded negative-sense R genome that encodes five structural proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), and R-dependent R polymerase (L). Among these viral proteins, the RABV glycoprotein (RABV-G) is a pivotal player mediating virus entry and the major target of neutralizing antibodies, thus a key factor for vaccine and drug design.A rapid and effective assay kit detecting the levels ofRABV-G is urgently needed to accelerate the development of RABV vaccines. |
SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development) |
RAS-A039 |
ACROBIOSYSTEMS |
96tests |
EUR 631.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines. |
Pam2CSK4 vaccine adjuvant; Biotin conjugate |
AV-9020-B |
Alpha Diagnostics |
1 mg |
EUR 489.6 |
Pam2CSK4 vaccine adjuvant; Biotin conjugate |
AV-9020-B-100 |
Alpha Diagnostics |
100 ug |
EUR 196.8 |
SARS-CoV-2 Spike RBD (XBB.1.5) ELISA Kit (For Vaccine Development) |
RAS-A146 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike RBD is urgently needed to accelerate the development of COVID-19 vaccines. |
SARS-CoV-2 Spike Trimer (XBB.1.5) ELISA Kit (For Vaccine Development) |
RAS-A145 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike Trimer is urgently needed to accelerate the development of COVID-19 vaccines. |
SARS-CoV-2 Spike Trimer (XBB.1) ELISA Kit (For Vaccine Development) |
RAS-A149 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike Trimer is urgently needed to accelerate the development of COVID-19 vaccines. |
Pam3CSK4 vaccine adjuvant; FITC labelled |
AV-9025-F |
Alpha Diagnostics |
100 ug |
EUR 416.4 |
Pertussis Toxin B.Pertussis, vaccine grade |
AV-9130-50 |
Alpha Diagnostics |
50 ug |
EUR 634.8 |
Peptidoglycan (S. aureus); vaccine adjuvant |
AV-7045-25 |
Alpha Diagnostics |
25 mg |
EUR 1220.4 |
Peptidoglycan (S. aureus); vaccine adjuvant |
AV-7045-5 |
Alpha Diagnostics |
5 mg |
EUR 343.2 |
Pam3CSK4 vaccine adjuvant; Biotin labelled |
AV-9025-B |
Alpha Diagnostics |
100 ug |
EUR 416.4 |
SARS-CoV-2 Spike S1 (B.1.1.529) Specific ELISA Kit (For Vaccine Development) |
RAS-A170 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike S1 is urgently needed to accelerate the development of COVID-19 vaccines. |
SARS-CoV-2 Spike RBD (B.1.1.529) Specific ELISA Kit (For Vaccine Development) |
RAS-A082 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines. |
SARS-CoV-2 Spike RBD (B.1.617.2) Specific ELISA Kit (For Vaccine Development) |
RAS-A092 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines. |
SARS-CoV-2 Spike Trimer (B.1.617.2) Specific ELISA Kit (For Vaccine Development) |
RAS-A055 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines. |
SARS-CoV-2 Spike Trimer (B.1.1.529) Specific ELISA Kit (For Vaccine Development) |
RAS-A081 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines. |
SARS-CoV-2 Spike Trimer (BA.4) Specific ELISA Kit (For Vaccine Development) |
RAS-A124 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines. |
SARS-CoV-2 Spike Trimer (BA.5) Specific ELISA Kit (For Vaccine Development) |
RAS-A125 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines. |
HER2 peptide, (369 ?377), E75 vaccine candidate |
HER2-369-P |
Alpha Diagnostics |
5 mg |
EUR 416.4 |
HER2 peptide, (654 ? 662), GP2 vaccine candidate |
HER2-654-P |
Alpha Diagnostics |
5 mg |
EUR 416.4 |
SARS-CoV-2 Spike RBD (Wild Type) Specific ELISA Kit (For Vaccine Development) |
RAS-A116 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines. |
Varicella Zoster Virus Glycoprotein E (VZV gE) ELISA Kit (For Vaccine Development) |
RAS-A135 |
ACROBIOSYSTEMS |
96tests |
EUR 631.3 |
|
Description: Varicella-zoster virus (VZV) the etiologic agent of chickenpox and herpes zoster [HZ], is highly contagious and still endemic worldwide. Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of Immunogenicity in the development of VZV vaccine.Therefore,It's helpful to develop the Varicella Zoster Virus Glycoprotein E (VZV gE) ELISA Kit to quantitative detection the VZV gE antigen in vaccine samples during the manufacture and quality control of vaccine development. |
HRSV (A) Pre-Fusion glycoprotein F0 Specific ELISA Kit (For Vaccine Development) |
RAS-A163 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: Respiratory syncytial virus (RSV) is a highly contagious virus causing severe infection in infants and the elderly. Various approaches are being used to develop an effective RSV vaccine. The RSV fusion (F) subunit, particularly the cleaved trimeric pre-fusion F, is one of the most promising vaccine candidates under development.A rapid and effective assay kit detecting the levels of HRSV (A) Pre-Fusion glycoprotein F0 is urgently needed to accelerate the development of RSV vaccines. |
HRSV (A) Post-Fusion glycoprotein F0 Specific ELISA Kit (For Vaccine Development) |
RAS-A169 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: Most in vitro RSV neutralizing antibodies in human sera are directed against the prefusion conformation, but due to its instability the prefusion conformation has a propensity to prematurely refold into the stable postfusion conformation, both in solution and on the surface of the virions. An RSV F protein that has both high expression levels and maintains a stable prefusion conformation would, therefore, be a promising subunit vaccine candidate against RSV. To facilitate the RSV-related research, drug trials and vaccine development,a rapid and effective assay kit detecting the specific levels of HRSV (A) Post-Fusion glycoprotein F0 is urgently needed to accelerate the development of RSV vaccines. |
Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to West Nile Virus vaccines (WNV-ENV/NS1/prM) vaccine by ELISA |
910-360-CUX |
Alpha Diagnostics |
Custom |
Ask for price |
Core Panel Multi-Tumor control slides, set of 5 |
TS900 |
Innovex |
Set of 5 |
EUR 145 |
Description: Core Panel Multi-Tumor control slides, set of 5 |
Core Panel Multi-Tumor control slides, set of 25 |
TS900-25 |
Innovex |
Set of 25 |
EUR 425 |
Description: Core Panel Multi-Tumor control slides, set of 25 |
Mouse Anti-Her2 Protein (ECD) ELISA kit for Her2 vaccine, 96 tests, Quantitative |
200-620-HRH |
Alpha Diagnostics |
1 Kit |
EUR 927.6 |
Purified Cholera Toxin protein; vaccine grade |
AV-9135-1000 |
Alpha Diagnostics |
1 mg |
EUR 781.2 |
Purified Cholera Toxin protein; vaccine grade |
AV-9135-500 |
Alpha Diagnostics |
500 ug |
EUR 416.4 |
SARS-CoV-2 Spike Trimer (Wild Type) Specific ELISA Kit (For Vaccine Development) |
RAS-A115 |
ACROBIOSYSTEMS |
96tests |
EUR 845.3 |
|
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines. |
Detection of Germline Mutations in Breast Most cancers Sufferers with Medical Options of Hereditary Most cancers Syndrome Utilizing a Multi-Gene Panel Take a look at.
Hereditary most cancers syndrome signifies that inherited genetic mutations can improve an individual’s danger of creating most cancers.
Tetranectin Polyclonal Antibody
We assessed the frequency of germline mutations utilizing an NGS-based multiple-gene panel containing 64-cancer predisposing genes in Korean breast most cancers sufferers with medical options of hereditary breast and ovarian most cancers syndrome (HBOC).A complete of 64 genes related to hereditary most cancers syndrome have been chosen for improvement of an NGS-based multi-gene panel.
Human Tetranectin (CLEC3B) ELISA Package
Focused sequencing utilizing the multi-gene panel was carried out to establish germline mutations in 496 breast most cancers sufferers with medical options of HBOC who underwent breast most cancers surgical procedure between January 2002 and December 2017.Of 496 sufferers, 95 sufferers (19.2%) have been discovered to have 48 deleterious germline mutations in 16 most cancers susceptibility genes.
Tetranectin Antibody |
49915-50ul |
SAB |
50ul |
EUR 286.8 |
ELISA kit for Human Tetranectin |
EK3337 |
SAB |
96 tests |
EUR 663.6 |
Description: Enzyme-linked immunosorbent assay kit for quantification of Human Tetranectin in samples from serum, plasma, tissue homogenates and other biological fluids. |
Human Tetranectin (CLEC3B) ELISA Kit |
abx252170-96tests |
Abbexa |
96 tests |
EUR 801.6 |
|
Human Tetranectin(CLEC3B) ELISA kit |
CSB-EL005531HU-24T |
Cusabio |
1 plate of 24 wells |
EUR 198 |
|
Description: Quantitativesandwich ELISA kit for measuring Human Tetranectin (CLEC3B) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price. |
Human Tetranectin(CLEC3B) ELISA kit |
1-CSB-EL005531HU |
Cusabio |
-
EUR 964.80
-
EUR 6118.80
-
EUR 3244.80
|
- 1 plate of 96 wells
- 10 plates of 96 wells each
- 5 plates of 96 wells each
|
|
Description: Quantitativesandwich ELISA kit for measuring Human Tetranectin(CLEC3B) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
Human Tetranectin(CLEC3B) ELISA kit |
E01T0030-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Human Tetranectin(CLEC3B) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human Tetranectin(CLEC3B) ELISA kit |
E01T0030-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Human Tetranectin(CLEC3B) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human Tetranectin(CLEC3B) ELISA kit |
E01T0030-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Human Tetranectin(CLEC3B) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human Tetranectin (CLEC3B) ELISA Kit |
IHUCLEC3BKT |
Innovative research |
each |
EUR 702 |
|
Description: Human Tetranectin (CLEC3B) ELISA Kit |
Human Tetranectin (CLEC3B) ELISA Kit |
RK08089 |
Abclonal |
96T |
EUR 280 |
Human Tetranectin(CLEC3B) ELISA kit |
E01A8123 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Recombinant Human Tetranectin Protein |
RP00991 |
Abclonal |
10 μg |
EUR 186 |
Human CLEC3B/ Tetranectin ELISA Kit |
E0507Hu |
Sunlong |
1 Kit |
EUR 685.2 |
Human CLEC3B(Tetranectin) ELISA Kit |
EH0279 |
FN Test |
96T |
EUR 681.12 |
|
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.469 ng/ml |
Human CLEC3B(Tetranectin) ELISA Kit |
E39EH0279 |
EnoGene |
96T |
EUR 595 |
Tetranectin (CLEC3B) Antibody |
abx231752-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
Tetranectin (CLEC3B) Antibody |
20-abx225113 |
Abbexa |
-
EUR 444.00
-
EUR 727.20
-
EUR 376.80
|
|
|
Tetranectin (CLEC3B) Antibody |
abx145920-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
Tetranectin (CLEC3B) Antibody |
20-abx125686 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Tetranectin (CLEC3B) Antibody |
20-abx320279 |
Abbexa |
|
|
|
Tetranectin (CLEC3B) Antibody |
20-abx004912 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Human Tetranectin, CLEC3B GENLISA ELISA |
KBH6262 |
Krishgen |
1 x 96 wells |
EUR 286 |
Tetranectin Rabbit mAb |
A4387-100ul |
Abclonal |
100 ul |
EUR 492 |
Tetranectin Rabbit mAb |
A4387-200ul |
Abclonal |
200 ul |
EUR 685.2 |
Tetranectin Rabbit mAb |
A4387-20ul |
Abclonal |
20 ul |
EUR 265.2 |
Tetranectin Rabbit mAb |
A4387-50ul |
Abclonal |
50 ul |
EUR 344.4 |
Tetranectin Rabbit pAb |
E2252010 |
EnoGene |
100ul |
EUR 225 |
Description: Available in various conjugation types. |
Tetranectin Rabbit mAb |
E2R25891 |
EnoGene |
100ul |
EUR 255 |
Description: Available in various conjugation types. |
Tetranectin Conjugated Antibody |
C49915 |
SAB |
100ul |
EUR 476.4 |
Tetranectin Polyclonal Antibody |
46862-100ul |
SAB |
100ul |
EUR 302.4 |
Tetranectin Polyclonal Antibody |
46862-50ul |
SAB |
50ul |
EUR 224.4 |
Tetranectin Polyclonal Antibody |
ABP60656-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A polyclonal antibody for detection of Tetranectin from Human, Mouse. This Tetranectin antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human Tetranectin protein at amino acid sequence of 11-60 |
Tetranectin Polyclonal Antibody |
ABP60656-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A polyclonal antibody for detection of Tetranectin from Human, Mouse. This Tetranectin antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human Tetranectin protein at amino acid sequence of 11-60 |
Tetranectin Polyclonal Antibody |
ABP60656-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of Tetranectin from Human, Mouse. This Tetranectin antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human Tetranectin protein at amino acid sequence of 11-60 |
Tetranectin Polyclonal Antibody |
ES8742-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against Tetranectin from Human/Mouse. This antibody is tested and validated for IHC, WB, ELISA |
Tetranectin Polyclonal Antibody |
ES8742-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against Tetranectin from Human/Mouse. This antibody is tested and validated for IHC, WB, ELISA |
Tetranectin Polyclonal Antibody |
E11-2035984 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
Tetranectin Polyclonal Antibody |
E046862 |
EnoGene |
100μg/100μl |
EUR 255 |
Description: Available in various conjugation types. |
Human Tetranectin/CLEC3B PicoKine ELISA Kit |
EK1253 |
BosterBio |
96 wells |
EUR 510 |
Description: For quantitative detection of human Tetranectin in cell culture supernates and serum. |
Recombinant Human Tetranectin Protein, His Tag |
E40KMP1408 |
EnoGene |
20ug |
EUR 495 |
Tetranectin/CLEC3B ELISA Kit (Human) (OKBB00562) |
OKBB00562 |
Aviva Systems Biology |
96 Wells |
EUR 606 |
Description: Description of target: Tetranectin, also called TNA, is a protein that in humans is encoded by the CLEC3B gene. It is mapped to 3p21.31. Tetranectin, a tetrameric protein isolated from human plasma, has 4 identical and noncovalently bound polypeptide chains, each of 181 amino acid residues. It has a specific binding affinity for sulfated polysaccharides and the kringle 4 of plasminogen. The plasma concentration of tetranectin is reduced in patients with various malignancies. Tetranectin is a plasminogen-binding protein that is induced during the mineralization phase of osteogenesis. Thus, tetranectin is a candidate gene for human disorders affecting bone and connective tissue.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich Immunoassay;Sensitivity: <= 10 pg/mL |
Recombinant Human CLEC3B/Tetranectin (C-6His) |
C453-10ug |
Novoprotein |
10ug |
EUR 157.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Human CLEC3B/Tetranectin (C-6His) |
C453-1mg |
Novoprotein |
1mg |
EUR 2739.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
The deleterious mutations have been present in 39 of 250 sufferers (15.6%) who had breast most cancers and one other main most cancers, 38 of 169 sufferers (22.5%) who had a household historical past of breast most cancers (≥ 2 family members), 16 of 57 sufferers (28.1%) who had bilateral breast most cancers, and 29 of 84 sufferers (34.5%) who have been recognized with breast most cancers at youthful than 40 years of age.
Human CellExp? CLEC3B / Tetranectin, Human recombinant
Of the 95 sufferers with deleterious mutations, 60 sufferers (63.2%) had BRCA1/2 mutations and 38 sufferers (40.0%) had non-BRCA1/2 mutations. We detected 2 novel deleterious mutations in BRCA2 and MLH1.NGS-based multiple-gene panel testing improved the detection charges of deleterious mutations and supplied a cheap most cancers danger evaluation.